Purpose: In order to evaluate fluorescent in situ hybridization (FISH) as a method for predicting radiosensitivity, this study examined the incidence of translocations, after exposure to in vitro radiation, in both normally responding patients and those exhibiting severe late effects after radiotherapy treatment. Materials and methods: Patients were selected from a randomized trial for intermediate-risk prostate cancer. Of the patients entered on trial with mature follow-up, 3% developed grade 3 late proctitis. Blood samples were taken from this radiosensitive cohort along with matched control patients with no late proctitis. Whole blood samples were exposed to 0 or 4 Gy and cultured according to the International Atomic Energy Agency (IAEA) recommended methods. Colour junctions were evaluated in the resulting metaphases and scored according to the Protocol for Aberration Identification and Nomenclature Terminology (PAINT) system. Results: Both groups were statistically similar at 0 Gy. After 4 Gy in vitro radiation, the radiosensitive group had significantly higher rates of chromosome damage in the number of colour junctions per cell (p = 0.002), the number of deletions per cell (p = 0.01) and the number of dicentrics per cell (p = 0.005). Conclusions: These results indicate that the analysis of translocations using FISH after in vitro irradiation correlates with clinical response to radiation. This cytogenetic assay should be considered as a potential predictor of radiosensitivity.

Additional Metadata
Keywords Chromosome damage, In vitro lymphocyte radiosensitivity, Late tissue response, Predictive assay, Prostate cancer, Translocations
Persistent URL dx.doi.org/10.3109/09553002.2013.825060
Journal International Journal of Radiation Biology
Citation
Beaton, L.A. (Lindsay A.), Marro, L. (Leonora), Samiee, S. (Sara), Malone, S. (Shawn), Grimes, S. (Scott), Malone, K. (Kyle), & Wilkins, R.C. (2013). Investigating chromosome damage using fluorescent in situ hybridization to identify biomarkers of radiosensitivity in prostate cancer patients. International Journal of Radiation Biology, 89(12), 1087–1093. doi:10.3109/09553002.2013.825060